6-methoxycarbonyl-3,4-dihydro-8-nitro-2(1H)-quinolinone | 165592-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-methoxycarbonyl-3,4-dihydro-8-nitro-2(1H)-quinolinone
• 英文别名: 8-nitro-6-methoxycarbonyl-3,4-dihydrocarbostyril；methyl 8-nitro-2-oxo-3,4-dihydro-1H-quinoline-6-carboxylate
• CAS: 165592-33-6
• 化学式: C₁₁H₁₀N₂O₅
• 分子量: 250.211
• InChiKey: WTMIKLWUUNGBRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-methoxycarbonyl-3,4-dihydro-8-nitro-2(1H)-quinolinone 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 diethylphosphoryl cyanide 、 三乙胺 、 过氧化苯甲酰 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 100.5h， 生成 6-(4-(N-methyl-2-phenylethyl)amino-1-piperidinyl)carbonyl-8-nitro-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o
• 作为产物：
  描述：

  2-羰基-1 ,2,3,4-四氢喹啉-6-羧酸 在 氯化亚砜 、 硫酸 、 硝酸 作用下， 反应 6.0h， 生成 6-methoxycarbonyl-3,4-dihydro-8-nitro-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o

文献信息

• [EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS<br/>[FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE
  申请人：COLLABORATIVE MEDICINAL DEV LLC

  公开号：WO2020185738A1

  公开（公告）日：2020-09-17

  The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.

  本申请公开了杂芳和杂双环芳香衍生物化合物和组合物，以及利用所公开的化合物和组合物治疗患者的铁死亡相关疾病和疾病的方法。
• Peripheral vasodilators
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05591751A1

  公开（公告）日：1997-01-07

  Peripheral vasodilating agents containing, as the active ingredient, carbostyril derivatives represented by the general formula: ##STR1## or a salt thereof; and novel carbostyril derivatives included within the scope of the above-mentioned general formula.

  含有周围血管扩张剂的药物，活性成分为一般式表示的卡波司烯衍生物，或其盐；以及包含在上述一般式范围内的新型卡波司烯衍生物。
• PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0636128A1

  公开（公告）日：1995-02-01
• HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS
  申请人：Collaborative Medicinal Development, LLC

  公开号：EP3938340A1

  公开（公告）日：2022-01-19
• US5591751A
  申请人：——

  公开号：US5591751A

  公开（公告）日：1997-01-07